newsfilter
← Latest News
Business Wire·

ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role

ERAS
  • Investors who purchased Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025, and April 26, 2026, may be eligible to join a securities fraud class action lawsuit.
  • The lead plaintiff appointment deadline is August 10, 2026, and applications filed after this date will not be considered by the Court.
  • The lawsuit alleges that Erasca, its CEO, & its CFO violated federal securities laws by making false statements regarding the drug candidate ERAS-0015.
  • Allegations include improper comparisons of preclinical data against Revolution Medicines' RMC-6236 & failure to disclose potential patent & trade secret disputes.
  • On April 27, 2026, Erasca disclosed a letter from RevMed alleging patent infringement & trade secret misappropriation regarding ERAS-0015.
  • Following the RevMed allegations on April 27, 2026, Erasca shares declined by 11% from $21.49 to $19.15.
  • On the same date, Erasca reported a preliminary Phase 1 clinical trial death involving a patient who developed Grade 3 TRAE pneumonitis progressing to Grade 5.
  • Erasca clarified that prior comparisons to other candidates were based on cross-study analyses rather than head-to-head trials & acknowledged data limitations.
  • Following the clinical trial death disclosure on April 27, 2026, Erasca shares declined by 48% from $19.15 to $9.90 on April 28, 2026.
  • Investors wishing to discuss rights or interests in the lawsuit can contact Lauren Molinaro of Kirby McInerney LLP via email at investigations@kmllp.com or through their contact form.